Affimed’s Supervisory Board is made up of highly experienced experts from the pharmaceutical and biotechnology industries
Dr. Hecht has been the Chairman of Affimed’s Supervisory Board since 2007. He is Head of Hecht Healthcare Consulting in Küssnacht, Switzerland, a biopharmaceutical consulting company founded in 2002. Dr. Hecht also serves as Chairman of Aelix Therapeutics and Orion Biotechnology and as member of the board of directors of BioInvent, Sweden.
Previously, Dr. Hecht served as a director of Humabs BioMed AG until August 2017 and he served as chairman of the board of directors of Cell Medica Ltd. Until the beginning of June 2020, he served as chairman of the board of directors of Vaximm AG, until March 2015, he served as chairman of the supervisory council of SuppreMol GmbH and until June 2016, of Delenex AG. Dr. Hecht was previously Vice President Marketing at Amgen Europe. A seasoned manager and industry professional, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, he was certified in internal medicine and served as Co-Head of the Program for Bone Marrow Transplantation at the University of Freiburg, Germany.
Chair of Audit Committee
Mr. Verdonck has been a member of Affimed’s Supervisory Board since July 2014. He is a Director and member of the Audit Committee of Virtus Funds and member of the Board of Laco Information Services. In recent years he was Chairman of the Supervisory Board of uniQure N.V., a member of the Board of Group SNEF and of J.P. Morgan European Investment Trust and a member of the Board of Directors and Chairman of the Audit Committee of two biotechnology companies in Belgium, Movetis and Galapagos.
He has previously served as Chairman of Banco Urquijo and of Nasdaq Europe and as a Director of Dictaphone Corporation. From 1992 to 2003, he was the Managing Director of Almanij NV, a financial services company which has since merged with KBC, and his responsibilities included company strategy, financial control, supervision of executive management and corporate governance, including board participation in publicly-traded and privately-held companies in many countries. Mr. Verdonck holds a law degree from KU Leuven and degrees in economics from KU Leuven and the University of Chicago.
Dr. Ehmer has been a member of Affimed’s Supervisory Board since 2016. He has been Chairman of the Board of Management of Biotest AG since January 2015. Prior to this, he worked for the Imclone Group, a wholly owned subsidiary of Eli Lilly, as President of Imclone Systems Corporation in the United States and as managing director in Germany.
In 2007/2008 he was CEO of Fresenius Biotech, Germany and before this, Dr. Ehmer headed the Business Area Oncology of Merck KGaA, Darmstadt and served as head of Global Clinical Operations at Merck. Between 1986 and 1998 he held various functions at Boehringer Mannheim in Germany, Italy and Singapore. Dr. Ehmer holds a degree in medicine and worked in the Department of Internal Medicine at the Academic Teaching Hospital of the University of Heidelberg.
Dr. Grau served as an advisor to Affimed’s board from May 2013 until June 2015 and became a board member in July 2015. He has over 30 years of experience in the biotechnology and pharmaceutical industries including general management, business development, corporate strategy and the development of new products and technologies.
Dr. Grau was Chief Operating Officer at Micromet from 2011 to 2012. Between 2006 and 2010, Dr. Grau was a founder, President and CEO of Lux Biosciences, Inc., a clinical stage ophthalmic company. Previously, Dr. Grau served as President of Research and Development at BASF Pharma/Knoll where he directed a global R&D organization whose development pipeline included Humira. The majority of his career was at Aventis Pharma, where he last held the position of Senior VP of Global Late Stage Development. Lantus® is based on his inventions made during his early years as a scientist with Hoechst AG. Dr. Grau received his Ph.D. in chemistry and biochemistry from the University of Stuttgart and spent three years as a post-doctoral fellow at Purdue University in the field of protein crystallography.
Dr. Simon has been a member of Affimed’s Supervisory Board since 2018. He was Executive Vice President and Chief Operating Officer of Cellectis (NASDAQ: CLLS), a company developing CAR-T cell immunotherapies and was appointed member of their Board of Directors in 2013. During his tenure, the company was transformed to a clinical-stage biopharmarmaceutical company.
Prior to joining Cellectis, he was Senior Vice President and Head of Global Pharmaceutical Operations at Pierre Fabre SA. From 1994 to 2010, Dr. Simon served at Wyeth Pharmaceuticals in both senior corporate and regional roles in the US and Europe (Head of International Marketing and Medical Affairs as well as Managing Director of several Wyeth affiliates).
Furthermore Dr. Simon is an advisor to the European Commission D.G. Research and Innovation and serves as Senior Strategic Advisor to Messier Maris Partners, a small international investment bank. He is chairman of the Board of Directors of Idorsia Pharmaceuticals (SWX – IDIA), Epsilen Bio and of Aileens Pharma.
Dr. Simon holds a degree in internal medicine from the Faculty of Medicine, Paris VII.
Mr. Welten serves as a member of Affimed’s Supervisory Board since August 2020. He serves as chairman and member of the board of directors of several biotechnology companies in Europe and the USA. Before becoming a full-time board of directors member starting in 2018 he served more than 18 years as Chief Financial Officer of both public as well as venture capital financed private biotech companies.
Prior to that, Harry has served in senior roles at UBS in Switzerland and New York for the first 15 years of his career. Mr. Welten has degrees in Banking, Finance and Economics as well as an MBA (honors) from Columbia University, NY, USA.
Dr. Jenkins has been a member of Affimed’s supervisory board since August 2020. She is a biopharma thought leader with over 25 years of industry experience. Dr. Jenkins has extensive recent experience in building and financing biotech companies pursuing cures for the most challenging rare diseases to address important medical issues globally. She has consistently built and led teams advancing programs from scientific research through clinical development, regulatory approval, and into healthcare systems globally. In addition, she is an advocate for diversity and inclusion, particularly for women in science.
Dr. Jenkins served as president and CEO of Dimension Therapeutics, a leading gene therapy company that she took public on the NASDAQ and subsequently sold to Ultragenyx. Prior leadership roles have included the head of global research and development and executive vice president global development and medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years – including serving as senior vice president and head of global medical affairs.
Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. Dr. Jenkins is a board member of several growing companies, including Oncimmune, AVROBIO, COMPASS Pathways (Nasdaq: CMPS), AOBiome, AgeX, PlaqueTec, ADOR Diagnostics, MedCity, DMNoMore, Conduit Connect, NoxSudor, Secret Saviours, Cocoon Biotech Inc. (Non-Executive Chair) and Genomics England.
She also is a committee member of the Science Board to the U.S. Food & Drug Administration, which advises FDA leadership on complex scientific and technical issues, board member at Faster Cures a center of The Milken Institute and Chair of The Court The London School of Hygiene and Tropical Medicine.